← CUMBERLAND PHARMACEUTICALS INC (CPIX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CUMBERLAND PHARMACEUTICALS INC (CPIX)
Pharmaceutical Preparations · market cap $118M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-03 (est.)
Earnings
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Cumberland Pharmaceuticals (CPIX) is a small-cap specialty pharma with 91 employees and a $98M market cap, generating roughly $40-45M in annual revenue from its marketed portfolio. Despite a pipeline spanning 20+ programs across Phase 2 and Phase 3 across pain, infections, hyponatremia, and rare diseases, the company has posted consistent net losses of $3-6M annually and carries only $11.4M in cash with no disclosed runway guidance.
The catalyst path
- 2026-11-03 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Intravenous ibuprofen | Phase 3 | Pain |
| YM087 | Phase 3 | Hyponatremia |
| YM087 oral | Phase 3 | Hyponatremia |
| Caldolor | Phase 3 | Burns |
| Telavancin | Phase 3 | Bacterial Pneumonia |
| Ifetroban | Phase 2 | Duchenne Muscular Dystrophy Cardiomyopathy |
| conivaptan | Phase 3 | Liver Cirrhosis |
| Ifetroban Injection | Phase 2 | Hepatorenal Syndrome |
| Ifetroban Sodium | Phase 2 | Idiopathic Pulmonary Fibrosis |
| Ifetroban Oral Capsule | Phase 2 | Asthma, Aspirin-Induced |
| Atorvastatin injection | Phase 2 | Hypercholesterolemia |
| Oral Ifetroban | Phase 2 | Scleroderma, Diffuse |
| 90 grams of Crystalline Lactulose | Phase 2 | Colonoscopy Preparation |
| Ifetroban, Oral Capsule | Phase 2 | Aspirin Exacerbated Respiratory Disease (AERD) |
| Full dose preparation | Phase 2 | Colonoscopy Preparation |
| N-Acetylcysteine (NAC) | Phase 2 | Radiocontrast Nephropathy |
| ranibizumab | Phase 2 | Retinal Vein Occlusion |
| Crystalline Lactulose | Phase 2 | Colonoscopy |
| Vancomycin | Phase 3 | Bacterial Pneumonia |
| ibuprofen | Phase 3 | Fever |
Price & technical context
3-month
+17.9%
6-month
+142.3%
12-month
+140.7%
52-wk range
$1.90–$8.97
vs 50-day MA
+1.6%
vs 200-day MA
+42.8%
Realized vol
93.3%
Max drawdown
-71.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CPIX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.